The relative effectiveness of eribulin for advanced breast cancer treatment: a study of the southeast Netherlands advanced breast cancer registry

References

• Eisai Ltd. ANNEX I: Summary of product characteristics Halaven. Eisai Ltd. EMA; 2011. Available from: https://www.ema.europa.eu/en/documents/product-information/halaven-epar-product-information_en.pdf.
   Google Scholar
• Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914–923.
   PubMed Web of Science ®Google Scholar
• Cardoso F. Metastatic breast cancer patients: the forgotten heroes! Breast. 2009;18(5):271–272.
   PubMed Web of Science ®Google Scholar
• Mol L, Koopman M, van Gils CW, et al. Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands. Acta Oncol. 2013;52(5):950.
   PubMed Web of Science ®Google Scholar
• Fleurence RL, Naci H, Jansen JP. The critical role of observational evidence in comparative effectiveness research. Health Affairs. 2010;29(10):1826–1833.
   Web of Science ®Google Scholar
• Aftimos P, Polastro L, Ameye L, et al. Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial. Eur J Cancer (Oxford, England: 1990). 2016;60:117–124.
   PubMed Web of Science ®Google Scholar
• Dell'Ova M, De Maio E, Guiu S, et al. Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study. BMC Cancer. 2015;15:659.
   PubMed Web of Science ®Google Scholar
• Gamucci T, Michelotti A, Pizzuti L, et al. Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study. J Cancer. 2014;5(5):320–327.
   PubMed Web of Science ®Google Scholar
• Garrone O, Montemurro F, Saggia C, et al. Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial – a multicenter retrospective study of eribulin in real life. Springerplus. 2016;5(1):59.
   PubMedGoogle Scholar
• Sabatier R, Dieras V, Pivot X, et al. Safety results and analysis of eribulin efficacy according to previous microtubules-inhibitors sensitivity in the french prospective expanded access program for heavily pre-treated metastatic breast cancer. Cancer Res Treat. 2018;50:1226–1237.
   PubMed Web of Science ®Google Scholar
• Dranitsaris G, Beegle N, Kalberer T, et al. A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting. J Oncol Pharm Pract. 2015;21(3):170–177.
   PubMed Web of Science ®Google Scholar
• Kikuchi Y, Uchida Y, Shirakawa K, et al. A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane-based regimens. Asia Pac J Clin Oncol. 2018;14(5):e231–e37.
   PubMed Web of Science ®Google Scholar
• Jacot W, Heudel PE, Fraisse J, et al. Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program. Int J Cancer. 2019.
   Web of Science ®Google Scholar
• Stuart EA. Matching methods for causal inference: a review and a look forward. Stat Sci. 2010;25(1):1–21.
   PubMed Web of Science ®Google Scholar
• Sekhon JS, Grieve RD. A matching method for improving covariate balance in cost-effectiveness analyses. Health Econ. 2012;21(6):695–714.
   PubMed Web of Science ®Google Scholar
• R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2017.
   Google Scholar
• Brems-Eskildsen AS, Kristoffersen KB, Linnet S, et al. Efficacy and toxicity of eribulin treatment in metastatic breast cancer patients. Acta Oncol. 2019;58(1):119–121.
   PubMed Web of Science ®Google Scholar
• Ates O, Babacan T, Kertmen N, et al. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer. J BUON. 2016;21(2):375–381.
   PubMed Web of Science ®Google Scholar
• Kessler L, Falato C, Margolin S, et al. A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden. Acta Oncol. 2015;54(4):522–529.
   PubMed Web of Science ®Google Scholar
• Poletti P, Ghilardi V, Livraghi L, et al. Eribulin mesylate in heavily pretreated metastatic breast cancer patients: current practice in an Italian community hospital. Future Oncol. 2014;10(2):233–239.
   PubMed Web of Science ®Google Scholar
• Ramaswami R, O’Cathail SM, Brindley JH, et al. Activity of eribulin mesylate in heavily pretreated breast cancer granted access via the Cancer Drugs Fund. Future Oncol. 2014;10(3):363–376.
   PubMed Web of Science ®Google Scholar
• Quaquarini E, Sottotetti F, D’Ambrosio D, et al. Eribulin across multiple lines of chemotherapy: a retrospective study on quality of life and efficacy in metastatic breast cancer patients. Future Oncol. 2017;13(11s):11–23.
   PubMed Web of Science ®Google Scholar
• Barni S, Livraghi L, Morritti M, et al. Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers – ESEMPiO study. Future Oncol. 2019;15(1):33–44.
   PubMed Web of Science ®Google Scholar
• Voutsadakis IA. A systematic review and pooled analysis of retrospective series of eribulin in metastatic breast cancer. Anti-cancer drugs. 2017;28(5):557–564.
   PubMed Web of Science ®Google Scholar
• Kaufman PA, Awada A, Twelves C, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33(6):594–601.
   PubMed Web of Science ®Google Scholar